Literature DB >> 20538481

Apolipoprotein B-to-A1 ratio as a predictor of acute ischemic nonembolic stroke in elderly subjects.

Michael S Kostapanos1, Leonidas G Christogiannis, Eftychia Bika, Eleni T Bairaktari, John A Goudevenos, Moses S Elisaf, Haralampos J Milionis.   

Abstract

Among traditional cardiovascular risk factors, apolipoprotein (apo)B/apoA1 ratio is considered to have the strongest predictive value for ischemic stroke. Nevertheless, there are imsufficient data to support this ratio as an independent risk predictor of ischemic stroke in elderly individuals. In this case-control study, we evaluated apoB/apoA1 ratio as a predictor of ischemic stroke in a cohort of elderly subjects. A total of 163 patients aged>70 years (88 men) admitted due to a first-ever acute ischemic/nonembolic stroke and 166 volunteers (87 men) with no history of cardiovascular disease were included. The association between apoB/apoA1 ratio and stroke was determined by multivariate logistic regression modeling after adjusting for potential confounding factors, including lipid parameters. Stroke patients exhibited a higher apoB/apoA1 ratio than controls (1.04±0.33 vs 0.86±0.22; P<.001). In univariate analysis, crude odds ratio (OR) for apoB/apoA1 ratio was 1.27 per 0.1 increase (95% confidence interval [CI]=1.15-1.39; P<.001). Compared with subjects with an apoB/apoA1 ratio in the lowest quartile, those within the highest quartile had a 6.3-fold increase in the odds of suffering an ischemic stroke (95% CI=3.17-12.48; P<.001). This association remained significant after controlling for potential confounders, including sex, age, smoking status, body mass index, waist circumference, glucose and insulin levels, the presence of hypertension and diabetes mellitus, and lipid profile parameters (adjusted OR=3.02; 95% CI=1.16-7.83; P=.02). Our findings support elevated apoB/apoA1 ratio as an independent predictor of ischemic stroke in individuals over age 70.
Copyright © 2010 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538481     DOI: 10.1016/j.jstrokecerebrovasdis.2009.09.010

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  6 in total

1.  R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke.

Authors:  Abdolkarim Mahrooz; Ghorban Gohari; Mohammad-Bagher Hashemi; Mehryar Zargari; Hadis Musavi; Mahmoud Abedini; Ahad Alizadeh
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

2.  Uric acid blood levels and relationship with the components of metabolic syndrome in hypertensive patients.

Authors:  M V Papavasileiou; A G Karamanou; P Kalogeropoulos; G Moustakas; S Patsianis; A Pittaras
Journal:  J Hum Hypertens       Date:  2015-07-02       Impact factor: 3.012

Review 3.  Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role.

Authors:  Richa Tyagi; Bhupesh Vaidya; Shyam Sunder Sharma
Journal:  Pharmacol Rep       Date:  2022-09-23       Impact factor: 3.919

Review 4.  Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case-control study.

Authors:  Hongli Dong; Wei Chen; Xiangyu Wang; Fuhua Pi; Yubin Wu; Shaojie Pang; Yuqing Xie; Fangfang Xia; Qingying Zhang
Journal:  Metab Brain Dis       Date:  2015-09-12       Impact factor: 3.584

5.  The correlation between serum apolipoprotein B/apolipoprotein A1 ratio and brain necrosis in patients underwent radiotherapy for nasopharyngeal carcinoma.

Authors:  Honghong Li; Dong Zheng; Fukang Xie; Xiaolong Huang; Xiaohuang Zhuo; Jinpeng Lin; Yi Li; Yamei Tang
Journal:  Brain Behav       Date:  2020-02-03       Impact factor: 2.708

6.  Predictive value of the apolipoprotein B/A1 ratio in intracerebral hemorrhage outcomes.

Authors:  Rasha Alsamani; Zhang Limin; Wu Jianwei; Wang Dan; Sun Yuehong; Liu Ziwei; Xu Huiwen; Wang Dongzhi; Shi Yijun; Qian Lingye; Zhao Xingquan; Zhang Guojun
Journal:  J Clin Lab Anal       Date:  2022-06-12       Impact factor: 3.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.